{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:48:07Z","timestamp":1794937687413,"version":"4.9.1"},"reference-count":273,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013301","name":"Parkinson&apos;s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.parkreldis.2020.11.017","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:38:11Z","timestamp":1605890291000},"page":"61-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Parkinson's disease and skin"],"prefix":"10.1016","volume":"82","author":[{"given":"Nicki","family":"Niemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Billnitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2020.11.017_bib1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson's disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/practneurol-2015-001107","article-title":"Parkinson's disease and the skin","volume":"15","author":"Gregory","year":"2015","journal-title":"Practical Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/CCID.S130319","article-title":"Skin disorders in Parkinson's disease: potential biomarkers and risk factors","volume":"10","author":"Ravn","year":"2017","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/mdc3.12425","article-title":"The skin and Parkinson's disease: review of clinical, diagnostic, and therapeutic issues","volume":"4","author":"Skorvanek","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14091","article-title":"An update on the microbiology, immunology and genetics of seborrheic dermatitis","volume":"29","author":"Adalsteinsson","year":"2020","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","article-title":"The onset of nonmotor symptoms in Parkinson's disease (the onset pd study)","volume":"30","author":"Pont-Sunyer","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnagi.2020.00060","article-title":"Association between Parkinson's disease and melanoma: putting the pieces together","volume":"12","author":"Ye","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1684\/ejd.2017.3066","article-title":"The association between bullous pemphigoid and neurological disorders: a systematic review","volume":"27","author":"Milani-Nejad","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting \u03b1-synuclein in Parkinson's disease: progress towards the development of disease-modifying therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson's disease biomarkers based on \u03b1\u2010synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib13","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.8b00383","article-title":"Alpha-synuclein in peripheral tissues in Parkinson's disease","volume":"10","author":"Ma","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.parkreldis.2019.03.003","article-title":"The aggregation state of \u03b1-synuclein deposits in dermal nerve fibers of patients with Parkinson's disease resembles that in the brain","volume":"64","author":"Kuzkina","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib15","series-title":"Int. Rev. Neurobiol","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/bs.irn.2017.05.005","article-title":"Neuropathology of nonmotor symptoms of Parkinson's disease","author":"Jellinger","year":"2017"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10286-018-0581-4","article-title":"Skin nerve \u03b1-synuclein deposits in Parkinson's disease and other synucleinopathies: a review","volume":"29","author":"Donadio","year":"2019","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","article-title":"Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease","volume":"382","author":"Schweitzer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28187","article-title":"Stem cells: scientific and ethical quandaries of a personalized approach to Parkinson's disease","author":"Jankovic","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib19","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1021\/acschemneuro.9b00498","article-title":"Association between Parkinson's disease and risk of cancer: a PRISMA-compliant meta-analysis","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib20","first-page":"697","article-title":"Parkinson's disease and cancer risk: a systematic review and meta-analysis","volume":"21","author":"Bajaj","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jnnp.2009.175463","article-title":"Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies","volume":"81","author":"Fois","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ana.410170514","article-title":"Low cancer rates among patients with Parkinson's disease","volume":"17","author":"Jansson","year":"1985","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1212\/01.wnl.0000277638.63767.b8","article-title":"Are Parkinson disease patients protected from some but not all cancers?","volume":"69","author":"Inzelberg","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.16462","article-title":"Parkinson's disease and skin cancer risk: a nationwide population-based cohort study in Korea","author":"Ryu","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib25","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.mayocp.2017.03.014","volume":"92","author":"Dalvin","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000494292","article-title":"Cancers preceding Parkinson's disease after adjustment for bias in a Danish population-based case-control study","volume":"52","author":"Cui","year":"2019","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00406","article-title":"Skin cancer may delay onset but not progression of Parkinson's disease: a nested case-control study","volume":"11","author":"Mahajan","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40035-015-0044-y","article-title":"The association between Parkinson's disease and melanoma: a systematic review and meta-analysis","volume":"4","author":"Huang","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib29","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1212\/WNL.0b013e3181bd13a1","article-title":"Family history of melanoma and Parkinson disease risk","volume":"73","author":"Gao","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000487855","article-title":"Parkinson's disease, melanoma, and keratinocyte carcinoma: a population-based study","volume":"50","author":"Lerman","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/mds.27807","article-title":"Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls","volume":"34","author":"Agalliu","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/DSS.0000000000000591","article-title":"A review of the association between Parkinson disease and malignant melanoma","volume":"42","author":"Disse","year":"2016","journal-title":"Dermatol. Surg."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JPD-171263","article-title":"Parkinson's disease and melanoma: Co-occurrence and mechanisms","volume":"8","author":"Bose","year":"2018","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib34","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/ijc.25912","article-title":"The association between Parkinson's disease and melanoma","volume":"128","author":"Pan","year":"2011","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mds.22855","article-title":"Skin cancer and Parkinson's disease","volume":"25","author":"Ferreira","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib37","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1212\/WNL.0b013e3181fb4466","article-title":"Common pathogenic pathways in melanoma and Parkinson disease","volume":"75","author":"Pais\u00e1n-Ruiz","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib38","first-page":"556","article-title":"Multiple primary melanoma following administration of levodopa","volume":"93","author":"Skibba","year":"1972","journal-title":"Arch. Pathol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/00207459208986663","article-title":"Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal Gland","volume":"63","author":"Sandyk","year":"1992","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1353-8020(03)00040-3","article-title":"Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?","volume":"9","author":"Fiala","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib41","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mds.21273","article-title":"Malignant melanoma in early Parkinson's disease: the DATATOP trial","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib42","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mds.21397","article-title":"Treatment with levodopa and risk for malignant melanoma","volume":"22","author":"Olsen","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib43","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0190-9622(98)70219-1","article-title":"Melanoma and levodopa","volume":"38","author":"Rampen","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib44","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1055-9965.EPI-07-0391","article-title":"Counterpoint: sunscreen use is a safe and effective approach to skin cancer prevention, Cancer Epidemiol","volume":"16","author":"Berwick","year":"2007","journal-title":"Biomarkers Prev"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib45","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/NXG.0000000000000070","article-title":"Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma","volume":"2","author":"Inzelberg","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv340","article-title":"PARKIN inactivation links Parkinson's disease to melanoma","volume":"108","author":"Hu","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jgg.2016.05.005","article-title":"Parkin somatic mutations link melanoma and Parkinson's disease","volume":"43","author":"Levin","year":"2016","journal-title":"J. Genet. Genomics."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00401-019-02110-z","article-title":"Overlapping genetic architecture between Parkinson disease and melanoma","volume":"139","author":"Dube","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib49","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00204-016-1757-0","article-title":"Melanin and neuromelanin binding of drugs and chemicals: toxicological implications","volume":"90","author":"Karlsson","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","article-title":"Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease","volume":"155","author":"Zucca","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib51","article-title":"The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells","volume":"7","author":"Pan","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.381","article-title":"Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis","volume":"4","author":"Chen","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/labinvest.2017.3","article-title":"Vitamin D signaling and melanoma: role of Vitamin D and its receptors in melanoma progression and management","volume":"97","author":"Slominski","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib54","doi-asserted-by":"crossref","first-page":"134778","DOI":"10.1016\/j.neulet.2020.134778","article-title":"Association between vitamin D receptor polymorphisms and susceptibility to Parkinson's disease: an updated meta-analysis","volume":"720","author":"Gao","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.21873\/anticanres.13988","article-title":"Association of Vitamin D receptor gene polymorphisms with melanoma risk: a meta-analysis and systematic review","volume":"40","author":"Birke","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib56","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ultrasmedbio.2018.11.010","article-title":"Accuracy of transcranial sonography of the substantia nigra for detection of Parkinson's disease: a systematic review and meta-analysis","volume":"45","author":"Tao","year":"2019","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.25233","article-title":"Sonographic abnormality of the substantia nigra in melanoma patients","volume":"28","author":"Rumpf","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib58","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/jnnp-2014-310239","article-title":"Frequency and profile of Parkinson's disease prodromi in patients with malignant melanoma","volume":"87","author":"Walter","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib59","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/mds.26427","article-title":"Light pigmentation phenotype is correlated with increased substantia nigra echogenicity","volume":"30","author":"Rumpf","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib60","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Canc. Biol. Ther."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0001-7310(07)70111-4","article-title":"Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis","volume":"98","author":"Peyr\u00ed","year":"2007","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/qjmed\/os-21.81.177","article-title":"The seborrhoeic facies as a manifestation of post-encephalitic parkinsonism and allied disorders","volume":"21","author":"Krestin","year":"1927","journal-title":"QJM. os-"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s007020170088","article-title":"Skin function and skin disorders in Parkinson's disease","volume":"108","author":"Fischer","year":"2001","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archderm.1971.04000170026005","article-title":"A new approach to the reduction of sebum secretion","volume":"103","author":"Harville","year":"1971","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib65","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1590\/1806-9282.65.6.791","article-title":"Dermatoses in parkinsonism: the importance of multidisciplinary follow-up","volume":"65","author":"Antunes","year":"2019","journal-title":"Rev. Assoc. Med. Bras."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib66","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00415-012-6557-8","article-title":"The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life","volume":"259","author":"Antonini","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib67","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/1523-1747.ep12682040","article-title":"Sebaceous gland secretion in Parkinson's disease during L-dopa treatment","volume":"60","author":"Kohn","year":"1973","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib68","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/BF01294730","article-title":"Is seborrhea a sign of autonomic impairment in Parkinson's disease?","volume":"104","author":"Martignoni","year":"1997","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib69","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-0404.1994.tb01675.x","article-title":"Could seborrhoeic dermatitis be implicated in the pathogenesis of parkinsonism?","volume":"89","author":"O'Neill","year":"1994","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1973.tb07545.x","article-title":"Sebum excretion in parkinsonism","volume":"88","author":"Burton","year":"1973","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib71","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1973.tb15453.x","article-title":"Effect of L-dopa on the seborrhoea of parkinsonism","volume":"88","author":"Burton","year":"1973","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib72","first-page":"93","article-title":"Excessive oiliness of the skin and paralysis agitans","volume":"54","author":"Cornbleet","year":"1946","journal-title":"Arch. Dermatol. Syphilol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.1999.tb00654.x","article-title":"Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome","volume":"99","author":"Charlett","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-5945-14-5","article-title":"A laboratory-based study on patients with Parkinson's disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production","volume":"14","author":"Arsic Arsenijevic","year":"2014","journal-title":"BMC Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archderm.1983.01650300027010","article-title":"Seborrheic dermatitis in neuroleptic-induced parkinsonism","volume":"119","author":"Binder","year":"1983","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib76","first-page":"73","article-title":"A 65-year-old man with rigid-bradykinetic parkinsonism, vertical gaze palsy, difficulty of eye-lid opening, and marked pseudo-bulbar palsy","volume":"57","author":"Noda","year":"2005","journal-title":"Brain Nerve"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1001\/archderm.1956.01550020010002","article-title":"Unilateral seborrheic dermatitis following a nerve lesion","volume":"73","author":"Bettley","year":"1956","journal-title":"A. M. A. Arch. Dermatology."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib78","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/1346-8138.12700","article-title":"Malassezia species and their associated skin diseases","volume":"42","author":"Harada","year":"2015","journal-title":"J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib79","series-title":"Park. Dis. Non-motor Non-dopaminergic Featur","first-page":"15","article-title":"Non-dopaminergic pathology of Parkinson's disease","author":"Braak","year":"2011"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/bjd.17826","article-title":"Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population-based study in 161 269 employees","volume":"181","author":"Zander","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib81","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fneur.2019.00758","article-title":"Malassezia and Parkinson's disease","volume":"10","author":"Laurence","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib82","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0306-9877(03)00094-X","article-title":"Seborrheic dermatitis, increased sebum excretion, and Parkinson's disease: a survey of (im)possible links","volume":"60","author":"Mastrolonardo","year":"2003","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib83","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.clinph.2014.03.024","article-title":"Forehead sympathetic skin responses in determining autonomic involvement in Parkinson's disease","volume":"125","author":"Sariahmetoglu","year":"2014","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib84","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S42.001","article-title":"Seborrheic dermatitis and risk of future Parkinson's disease (PD) [meeting abstract]","volume":"78","author":"Tanner","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib85","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(73)91885-0","article-title":"MELANOCYTE-STIMULATING hormone and parkinsonism","volume":"301","author":"Shuster","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0140-6736(70)92476-1","article-title":"Effect of l-dopa on seborrhoea of parkinsonism","volume":"296","author":"Burton","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib87","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0140-6736(71)91782-X","article-title":"Sebum-excretion rate and skin-surface lipid composition in Parkinson's disease before and during therapy with levodopa","volume":"297","author":"Cotterill","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2133.1990.tb08241.x","article-title":"The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders","volume":"122","author":"Cowley","year":"1990","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib89","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1523-1747.ep12277224","article-title":"Age-related changes in sebaceous wax ester secretion rates in men and women","volume":"85","author":"Jacobsen","year":"1985","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib90","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.286.6372.1169","article-title":"Seborrhoea is not a feature of seborrhoeic dermatitis","volume":"286","author":"Burton","year":"1983","journal-title":"Br. Med. J."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fcimb.2020.00112","article-title":"Malassezia-associated skin diseases, the use of diagnostics and treatment","volume":"10","author":"Saunte","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib92","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.01.001","article-title":"Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies","volume":"31","author":"Dessinioti","year":"2013","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/jocd.12866","article-title":"Efficacy and possible mechanisms of botulinum toxin treatment of oily skin","volume":"18","author":"Shuo","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib94","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1473-2165.2006.00250.x","article-title":"Botulinum toxin in dermatology - beyond wrinkles and sweat","volume":"5","author":"Diamond","year":"2006","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib95","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s00415-019-09325-w","article-title":"Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson's disease","volume":"266","author":"van Wamelen","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1353-8020(02)00032-9","article-title":"Are electrophysiological autonomic tests useful in the assessment of dysautonomia in Parkinson's disease?","volume":"9","author":"Zakrzewska-Pniewska","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib97","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3346\/jkms.2009.24.2.311","article-title":"Non-motor off symptoms in Parkinson's disease","volume":"24","author":"Cheon","year":"2009","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib98","first-page":"160","article-title":"Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire","volume":"1","author":"Crosiers","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib99","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00415-011-6392-3","article-title":"Gender-related differences in the burden of non-motor symptoms in Parkinson's disease","volume":"259","author":"Martinez-Martin","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clineuro.2009.11.015","article-title":"Effects of subthalamic nucleus deep brain stimulation on sweating function in Parkinson's disease","volume":"112","author":"Trachani","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib101","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/jnnp.39.11.1092","article-title":"Dysautonomia in Parkinsonism: a clinicopathological study","volume":"39","author":"Rajput","year":"1976","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib102","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bmj.4.5779.80","article-title":"Assessment of autonomic function in patients with a parkinsonian syndrome","volume":"4","author":"Aminoff","year":"1971","journal-title":"Br. Med. J."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib103","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/1531-8257(200011)15:6<1215::AID-MDS1023>3.0.CO;2-J","article-title":"Sympathetic skin response and cardiovascular autonomic function tests in Parkinson's disease and multiple system atrophy with autonomic failure","volume":"15","author":"De Marinis","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib104","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/mds.21006","article-title":"Hyperhidrosis in Parkinson's disease","volume":"21","author":"Schestatsky","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00415-012-6600-9","article-title":"Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease","volume":"260","author":"\u0160pica","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib106","first-page":"E180","article-title":"Investigation of the treatment and living assistance needed by patients with young-onset Parkinson's disease","volume":"64","author":"Iwasa","year":"2018","journal-title":"Kobe J. Med. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib107","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.59.3.408","article-title":"Nonmotor fluctuations in Parkinson's disease: frequent and disabling","volume":"59","author":"Witjas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib108","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2017.1125","article-title":"Association of autonomic dysfunction with disease progression and survival in Parkinson disease","volume":"74","author":"De Pablo-Fernandez","year":"2017","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.11.017_bib109","first-page":"734","article-title":"Thermal sudomotor deficits in Parkinson\u2019s disease","volume":"29","author":"Saito","year":"1989","journal-title":"Clin. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.410370124","article-title":"Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile","volume":"37","author":"Sage","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib111","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/mds.10586","article-title":"Sweating dysfunction in Parkinson's disease","volume":"18","author":"Swinn","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib112","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.gaitpost.2014.05.011","article-title":"Characteristics of non-motor symptoms in patients with Parkinson's disease exhibiting camptocormia","volume":"40","author":"Ou","year":"2014","journal-title":"Gait Posture"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib113","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4103\/aian.AIAN_459_17","article-title":"A comparative study of early and late onset freezing of gait in Parkinson's disease","volume":"21","author":"Prasad","year":"2018","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib114","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2012.02.023","article-title":"The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy","volume":"317","author":"Kimpinski","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archneurol.2009.71","article-title":"Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure","volume":"66","author":"Lipp","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib116","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clineuro.2014.10.006","article-title":"Non-motor fluctuations in Parkinson's disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients","volume":"127","author":"Brun","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib117","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","article-title":"Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications","volume":"80","author":"Storch","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib118","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.parkreldis.2010.08.022","article-title":"Multi-organ autonomic dysfunction in Parkinson disease","volume":"17","author":"Jain","year":"2011","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib119","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib120","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00702-019-02060-6","article-title":"New methods of assessing autonomic disorders in Parkinson disease patients: skin-galvanic reaction","volume":"126","author":"Dutkiewicz","year":"2019","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib121","first-page":"38","article-title":"Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease","volume":"111","author":"Levin","year":"2011","journal-title":"Zhurnal Nevrol. i Psihiatr. Im. S.S. Korsakova."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib122","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3233\/JPD-2011-11037","article-title":"Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect","volume":"1","author":"Martinez-Martin","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib123","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/j.1600-0404.2012.01648.x","article-title":"Effect of duodenal levodopa infusion on blood pressure and sweating","volume":"126","author":"Pursiainen","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib124","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib125","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jns.2009.06.019","article-title":"Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinson's disease - a case report","volume":"285","author":"Sanghera","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib126","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/mds.21602","article-title":"Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease","volume":"22","author":"Witjas","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib127","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jocn.2010.10.015","article-title":"Effect of deep brain stimulation on autonomic dysfunction in patients with Parkinson's disease","volume":"18","author":"Halim","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib128","article-title":"Effect of deep brain stimulation on Parkinson's nonmotor symptoms following unilateral DBS: a pilot study","volume":"2011","author":"Hwynn","year":"2011","journal-title":"Parkinsons. Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00701-019-04182-y","article-title":"The effects of chronic subthalamic stimulation on nonmotor symptoms in advanced Parkinson's disease, revealed by an online questionnaire program","volume":"162","author":"Kawaguchi","year":"2020","journal-title":"Acta Neurochir."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib130","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.parkreldis.2012.05.011","article-title":"Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease","volume":"18","author":"Wolz","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib131","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jocn.2013.07.012","article-title":"Deep brain stimulator-induced diaphoresis in Parkinson's disease patients","volume":"21","author":"Lam","year":"2014","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib132","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2016.04.045","article-title":"Hyperhidrosis associated with subthalamic deep brain stimulation in Parkinson's disease: insights into central autonomic functional anatomy","volume":"366","author":"Ramirez-Zamora","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib133","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1212\/01.wnl.0000174436.36399.ca","article-title":"Sympathetic activation due to deep brain stimulation in the region of the STN","volume":"65","author":"Lipp","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib134","first-page":"8180123","article-title":"Analysis of contact position for subthalamic nucleus deep brain stimulation-induced hyperhidrosis","volume":"2019","author":"Yang","year":"2019","journal-title":"Parkinsons. Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib135","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib136","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib137","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib138","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5114\/ada.2017.65619","article-title":"Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson's disease is more relevant to bullous pemphigoid","volume":"34","author":"Bartkiewicz","year":"2017","journal-title":"Postep. Dermatologii i Alergol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib140","doi-asserted-by":"crossref","first-page":"637","DOI":"10.17219\/acem\/90922","article-title":"The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: case-control study in a specialized Polish center","volume":"28","author":"Kalinska-Bienias","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib141","first-page":"1","article-title":"Frequency of neurological disorders in bullous pemphigoid patients: a cross-sectional study","author":"Khosravani","year":"2017","journal-title":"Int. Sch. Res. Not."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib142","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib143","first-page":"81","article-title":"The association between bullous pemphigoid and neurological disorders in a selected Malaysian population","volume":"70","author":"Kwan","year":"2015","journal-title":"Med. J. Malaysia"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib144","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case-control study","volume":"131","author":"Langan","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib145","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jid.2019.01.034","article-title":"Demographics and autoantibody profiles of pemphigoid patients with underlying neurologic diseases","volume":"139","author":"Messingham","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib146","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jdv.15444","article-title":"Neurological disorders are associated with bullous pemphigoid","volume":"33","author":"Papakonstantinou","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib147","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4103\/0378-6323.198451","article-title":"Bullous pemphigoid and antecedent neurological diseases: an association with dementia","volume":"83","author":"Phuan","year":"2017","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib148","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/bjd.14821","article-title":"Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A","volume":"176","author":"Ren","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib149","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/jdv.14312","article-title":"Multimorbidity in bullous pemphigoid: a case\u2013control analysis of bullous pemphigoid patients with age- and gender-matched controls","volume":"31","author":"Sim","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib150","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: A prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib151","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: A case-control study","volume":"146","author":"Taghipour","year":"2010","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib152","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1590\/abd1806-4841.20142516","article-title":"Bullous pemphigoid and comorbidities: A case-control study in Portuguese patients","volume":"89","author":"Teixeira","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib153","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","article-title":"Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland, Arch","volume":"309","author":"Kalinska-Bienias","year":"2017","journal-title":"Dermatol. Res."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib154","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40520-015-0459-4","article-title":"Bullous pemphigoid and neurodegenerative diseases: a study in a setting of a Central European university dermatology department","volume":"28","author":"Pietkiewicz","year":"2016","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib155","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaad.2014.07.052","article-title":"A population-based study of the association between bullous pemphigoid and neurologic disorders","volume":"71","author":"Brick","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib156","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: Risk factors and causes of death in 359 patients seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib157","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ad.2014.04.013","article-title":"Association Between Bullous Pemphigoid and Neurologic Diseases: A Case-Control Study","volume":"105","author":"Casas-De-La-Asunci\u00f3n","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib158","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000106574","article-title":"Neurological disorders in patients with bullous pemphigoid","volume":"215","author":"Cordel","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib159","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/0378-6323.191132","article-title":"Neurological diseases and bullous pemphigoid: A case-control study in Iranian patients","volume":"83","author":"Daneshpazhooh","year":"2017","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib160","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/jdv.12995","article-title":"Neurological disorders in patients with bullous pemphigoid: Clinical and experimental investigations","volume":"29","author":"Gambichler","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib161","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5021\/ad.2018.30.1.13","article-title":"Mortality and comorbidity profiles of patients with bullous pemphigoid in Korea","volume":"30","author":"Jeon","year":"2018","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib163","article-title":"Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment","volume":"10","author":"Di Lernia","year":"2020","journal-title":"Dermatol. Pract. Concept."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib164","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib165","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaneurol.2016.0022","article-title":"Exploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study","volume":"73","author":"Egeberg","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib166","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1111\/jdv.14638","article-title":"Rosacea and subsequent diagnosis for Parkinson's disease: a large, urban, single center, US patient population retrospective study","volume":"32","author":"Mathieu","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib167","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamaneurol.2016.2321","article-title":"Association Between Rosacea and Parkinson Disease","volume":"73","author":"Alexoudi","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib168","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","article-title":"Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee","volume":"82","author":"Thiboutot","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib169","doi-asserted-by":"crossref","DOI":"10.1007\/s00455-020-10102-5","article-title":"Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study","author":"van Wamelen","year":"2020","journal-title":"Dysphagia"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib170","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-009-5144-0","article-title":"Debilitating consequences of drooling","volume":"256","author":"Bloem","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib171","first-page":"28196","article-title":"Glycopyrrolate Improves Disability from Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial","author":"Mestre","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib172","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","article-title":"Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial","volume":"77","author":"Isaacson","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib173","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14728214.2020.1729120","article-title":"Managing autonomic dysfunction in Parkinson's disease: a review of emerging drugs","volume":"25","author":"Kulshreshtha","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib174","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","article-title":"Initiation of pharmacological therapy in Parkinson's disease: when, why, and how","volume":"19","author":"de Bie","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib175","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13760-019-01195-3","article-title":"Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach","volume":"119","author":"Bougea","year":"2019","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib176","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1212\/01.wnl.0000257823.27573.3d","article-title":"Skin rash associated with Sinemet does not equal levodopa allergy","volume":"68","author":"Chou","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib177","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/WNF.0000000000000270","article-title":"Allergy to Carbidopa","volume":"41","author":"Cansino-Torres","year":"2018","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib178","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mdc3.12669","article-title":"Skin Allergy Associated to Different Formulations of Levodopa","volume":"5","author":"Da Prat","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib179","doi-asserted-by":"crossref","first-page":"4","DOI":"10.14802\/jmd.09002","article-title":"Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson's Disease","volume":"2","author":"Antonini","year":"2009","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib180","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/DDDT.S229621","article-title":"The advantages of Levodopa-Carbidopa intestinal gel for patients with advanced Parkinson's disease: A systematic review","volume":"14","author":"Zhang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib181","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1038\/ctg.2016.19","article-title":"Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease","volume":"7","author":"Epstein","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib182","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.737","article-title":"Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease","volume":"7","author":"Udd","year":"2017","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib183","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: A randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib184","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/mds.22450","article-title":"Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease","volume":"24","author":"Devos","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib185","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1007\/s00415-019-09337-6","article-title":"Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa\/carbidopa intestinal gel: final results of the GREENFIELD observational study","volume":"266","author":"Lopiano","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib186","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/mdc3.12630","article-title":"Implementing Levodopa-Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners","volume":"5","author":"Burack","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib187","article-title":"Lack of Notable Skin Reactions from a Novel Levodopa\/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site [abstract]","volume":"34","author":"Facheris","year":"2019","journal-title":"Mov. Disord."},{"issue":"15","key":"10.1016\/j.parkreldis.2020.11.017_bib188","article-title":"ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson's Disease Patients (543)","volume":"94","author":"Rosebraugh","year":"2020","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.parkreldis.2020.11.017_bib189","article-title":"Safety and Tolerability During a 4-Week Continuous Subcutaneous Infusion of ABBV-951, a New Drug Formulation for the Treatment of Parkinson's Disease: Final Results of a Phase 1b Study (1384)","volume":"94","author":"Facheris","year":"2020","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.parkreldis.2020.11.017_bib190","article-title":"Continuous Administration of Subcutaneous Levodopa\/Carbidopa (ND0612) Demonstrated Comparable Levodopa Pharmacokinetics to Levodopa\/Carbidopa Intestinal Gel (LCIG) (S4.003)","volume":"88","author":"Adar","year":"2017","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.parkreldis.2020.11.017_bib191","article-title":"First Results for The BeyoND Study: An open-label international, multicenter study evaluating the long-term safety of ND0612 in patients with idiopathic Parkinson's disease (4444)","volume":"94","author":"Isaacson","year":"2020","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.parkreldis.2020.11.017_bib192","article-title":"Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506)","volume":"94","author":"Ellenbogen","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib193","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JPD-199005","article-title":"Clinical Trial Highlights-Infusion Therapies","volume":"10","author":"Prakash","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib194","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/00207454.2012.668727","article-title":"Patient perception of levido reticularis due to amantadine","volume":"122","author":"Rana","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib196","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.2.5762.627","article-title":"Livedo reticularis during amantadine treatment","volume":"2","author":"Vollum","year":"1971","journal-title":"Br. Med. J."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib197","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2004.11.051","article-title":"Livedo reticularis: An update","volume":"52","author":"Gibbs","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib198","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00415-005-0967-9","article-title":"The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa A literature review","volume":"252","author":"Kraemer","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib199","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1212\/WNL.53.8.1862","article-title":"Amantadine-induced peripheral neuropathy","volume":"53","author":"Shulman","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib200","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.1970.03170220076019","article-title":"Livedo Reticularis in Patients With Parkinsonism Receiving Amantadine","volume":"212","author":"Shealy","year":"1970","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib201","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/11206750-000000000-00000","article-title":"Rotigotine transdermal patch: A review of its use in the treatment of parkinsons disease","volume":"25","author":"Sanford","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib202","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson Disease: A 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib203","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/ene.12375","article-title":"Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease","volume":"21","author":"Hauser","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib204","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3109\/00207454.2010.546538","article-title":"Long-term, open-label study of once-daily ropinirole prolonged release in early parkinson's disease","volume":"121","author":"Hauser","year":"2011","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib205","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archneur.64.6.noc60158","article-title":"Risk factors for the development of pedal edema in patients using pramipexole","volume":"64","author":"Kleiner-Fisman","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib206","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archneur.57.5.729","article-title":"Clinical characteristics of pramipexole-induced peripheral edema","volume":"57","author":"Tan","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib207","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson's disease: A mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib208","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1212\/WNL.31.10.1368","article-title":"Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine","volume":"31","author":"Eisler","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib209","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2133.1984.tb04022.x","article-title":"Erythromelalgia following pergolide administration","volume":"111","author":"Monk","year":"1984","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12508","article-title":"Rotigotine transdermal system: Developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome","volume":"1329","author":"Benitez","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib211","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.clinthera.2012.02.008","article-title":"Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies","volume":"34","author":"Elshoff","year":"2012","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib212","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1517\/14740338.2012.678830","article-title":"Drug safety evaluation of rotigotine","volume":"11","author":"Sprenger","year":"2012","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib213","series-title":"Highlights of Prescribing Information. Neupro (Rotigotine)","year":"2020"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib214","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28027","article-title":"Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients","volume":"35","author":"Olanow","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib215","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1586\/ern.09.48","article-title":"Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: Selection criteria and patient management","volume":"9","author":"Antonini","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib216","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","article-title":"Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations","volume":"33","author":"Carbone","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib217","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib218","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-004-0547-4","article-title":"A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease","volume":"251","author":"Tyne","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib219","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib220","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1365-2133.1998.02128.x","article-title":"Panniculitis in association with apomorphine infusion","volume":"138","author":"Acland","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib221","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/mds.23832","article-title":"Apomorphine-induced necrotic ulcers","volume":"26","author":"Ganesalingam","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib222","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.parkreldis.2012.04.012","article-title":"Multiple subcutaneous abscesses and necroses due to apomorphine pump treatment","volume":"18","author":"Wojtecki","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib223","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00415-010-5793-z","article-title":"A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation","volume":"258","author":"Antonini","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib224","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.parkreldis.2019.06.011","article-title":"Severe abdominal panniculitis in a patient treated with continuous subcutaneous apomorphine infusion","volume":"65","author":"Querejeta-Coma","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib225","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib226","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/mds.22316","article-title":"Ultrasound treatment of cutaneous side-effects of infused apomorphine: A randomized controlled pilot study","volume":"24","author":"Poltawski","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib227","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","article-title":"CTH-300 Study investigators, Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study","volume":"19","author":"Olanow","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib228","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMct1208070","article-title":"Deep-brain stimulation for Parkinson's disease","volume":"367","author":"Okun","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib229","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.23800","article-title":"Diagnosis and treatment of complications related to deep brain stimulation hardware","volume":"26","author":"Baizabal Carvallo","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib230","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.brs.2017.07.003","article-title":"Systematic review of hardware-related complications of Deep Brain Stimulation: Do new indications pose an increased risk?","volume":"10","author":"Jitkritsadakul","year":"2017","journal-title":"Brain Stimul"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib231","first-page":"1","article-title":"Reoperation for device infection and erosion following deep brain stimulation implantable pulse generator placement","author":"Atchley","year":"2019","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib232","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100003966","article-title":"Reducing hardware-related complications of deep brain stimulation","volume":"32","author":"Constantoyannis","year":"2005","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib233","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/ner.12335","article-title":"Long-Term Evaluation of Changes in Operative Technique and Hardware-Related Complications with Deep Brain Stimulation","volume":"18","author":"Falowski","year":"2015","journal-title":"Neuromodulation"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib234","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mdc3.12592","article-title":"Challenges in PD Patient Management After DBS: A Pragmatic Review","volume":"5","author":"Rossi","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000316762","article-title":"Avoidance and management of surgical and hardware-related complications of deep brain stimulation","volume":"88","author":"Hu","year":"2010","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib236","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1227\/01.neu.0000316002.03765.33","article-title":"Deep brain stimulator hardware-related infections: Incidence and management in a large series","volume":"62","author":"Sillay","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib237","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib238","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib239","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib240","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease","volume":"86","author":"Rizzo","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib241","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","article-title":"Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study","volume":"83","author":"Adler","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib242","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1212\/WNL.0b013e3182825127","article-title":"Skin sympathetic fiber \u03b1-synuclein deposits: A potential biomarker for pure autonomic failure","volume":"80","author":"Donadio","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib243","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1212\/WNL.0000000000004146","article-title":"A new potential biomarker for dementia with Lewy bodies","volume":"89","author":"Donadio","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib244","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/WNL.0000000000000316","article-title":"Skin nerve -synuclein deposits: A biomarker for idiopathic Parkinson disease","volume":"82","author":"Donadio","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib245","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"\u03b1-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib246","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2014.00042","article-title":"Protein phosphorylation in neurodegeneration: friend or foe?","volume":"7","author":"Tenreiro","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib247","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1212\/WNL.0b013e3182a9f449","article-title":"\u03b1-Synuclein in cutaneous autonomic nerves","volume":"81","author":"Wang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib248","doi-asserted-by":"crossref","first-page":"14246","DOI":"10.1038\/s41598-018-32588-8","article-title":"Skin \u03b1-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study","volume":"8","author":"Donadio","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib249","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/NEN.0b013e318186de48","article-title":"Lewy body pathology involves cutaneous nerves","volume":"67","author":"Ikemura","year":"2008","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib250","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated \u03b1-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib251","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/mds.25776","article-title":"Multiple organ involvement by alpha-synuclein pathology in lewy body disorders","volume":"29","author":"Gelpi","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib252","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-171088","article-title":"Cutaneous Alpha-Synuclein from Paraffin Embedded Autopsy Specimens in Parkinson's Disease","volume":"7","author":"Gibbons","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib253","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","article-title":"Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease","volume":"133","author":"Doppler","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib254","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/acn3.669","article-title":"Cervical skin denervation associates with alpha-synuclein aggregates in Parkinson disease","volume":"5","author":"Melli","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib255","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/brain\/awaa008","article-title":"\u03b1-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson's disease","volume":"143","author":"Mazzetti","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib256","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1463","article-title":"Reduced central sympathetic activity in Parkinson's disease","volume":"9","author":"Kr\u00e4mer","year":"2019","journal-title":"Brain Behav"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib257","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/ene.13939","article-title":"Abnormal \u03b1-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility","volume":"26","author":"Donadio","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib258","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neulet.2009.12.027","article-title":"Clinical availability of skin biopsy in the diagnosis of Parkinson's disease","volume":"469","author":"Miki","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib259","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-014-1284-0","article-title":"Cutaneous neuropathy in Parkinson's disease: A window into brain pathology","volume":"128","author":"Doppler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib260","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.24567","article-title":"Skin nerve misfolded \u03b1-synuclein in pure autonomic failure and Parkinson disease","volume":"79","author":"Donadio","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib261","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/mds.26293","article-title":"Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy","volume":"30","author":"Doppler","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib262","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.0000000000002919","article-title":"The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease","volume":"87","author":"Gibbons","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib263","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00702-014-1355-3","article-title":"Cutaneous autonomic denervation in Parkinson's disease","volume":"122","author":"Navarro-Otano","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib264","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/brain\/awv138","article-title":"Phosphorylated \u03b1-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy","volume":"138","author":"Zange","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib265","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/mds.27794","article-title":"Value of in vivo \u03b1-synuclein deposits in Parkinson's disease: A systematic review and meta-analysis","volume":"34","author":"Tsukita","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib266","first-page":"1113","article-title":"Optimization of the Detection Method for Phosphorylated \u03b1-Synuclein in Parkinson Disease by Skin Biopsy","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib267","doi-asserted-by":"crossref","first-page":"e1267","DOI":"10.1212\/WNL.0000000000010404","article-title":"Systemic Synuclein Sampling Study, In vivo distribution of \u03b1-synuclein in multiple tissues and biofluids in Parkinson disease","volume":"95","author":"Chahine","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib268","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28126","article-title":"Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease with Orthostatic Hypotension","author":"Donadio","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib269","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jnen\/nly074","article-title":"Skin nerve phosphorylated a-synuclein deposits in Parkinson disease with orthostatic hypotension","volume":"77","author":"Donadio","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib270","doi-asserted-by":"crossref","DOI":"10.1093\/jnen\/nlaa048","article-title":"A Longitudinal Skin Biopsy Study of Phosphorylated Alpha-Synuclein in a Patient With Parkinson Disease and Orthostatic Hypotension","volume":"79","author":"Infante","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib271","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","article-title":"Discriminating \u03b1-synuclein strains in Parkinson's disease and multiple system atrophy","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib272","doi-asserted-by":"crossref","DOI":"10.1002\/mds.28242","article-title":"Blinded RT-QuIC Analysis of \u03b1-Synuclein Biomarker in Skin Tissue from Parkinson's Disease Patients","author":"Manne","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.11.017_bib273","article-title":"Skin \u03b1-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease","author":"Wang","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.parkreldis.2020.11.017_bib274","doi-asserted-by":"crossref","first-page":"685","DOI":"10.21037\/atm.2019.11.16","article-title":"A compendious summary of Parkinson's disease patient-derived iPSCs in the first decade","volume":"7","author":"Ren","year":"2019","journal-title":"Ann. Transl. Med."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020308671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020308671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:20:55Z","timestamp":1761178855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020308671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":273,"alternative-id":["S1353802020308671"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.11.017","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parkinson's disease and skin","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}